Modified Weight Loss Vaccine Alters Cell Behavior for Long-Term Weight Management
In a significant breakthrough for the treatment of type 2 diabetes, particularly among children aged 10 to 17, the drug Tirzepatide, marketed under the brand name Mounjaro by Eli Lilly, has shown remarkable improvements. This drug is the first to demonstrate sustained clinically meaningful BMI-lowering effects in this age group.
The drug works by affecting how the body breaks down and uses fats, the production and activity of mitochondria, the organization and function of body fat, and changes in how body fat is utilized. Tirzepatide also reprograms how cells handle fat and energy.
In a study involving 99 young people, half were given Tirzepatide, and the other half received a placebo. After 30 weeks, 79% of participants who took Tirzepatide had blood sugar levels below 6.5%, compared to no change among those who took the placebo. Moreover, 53% of participants had blood sugar levels below 5.7%, a range considered below pre-diabetes.
The authors of the study concluded that Tirzepatide demonstrated significant and clinically meaningful improvements in blood sugar control and BMI. Nikki Joule, policy manager at Diabetes UK, commented that the study highlights Tirzepatide as a much-needed potential option for improving how we treat and care for young people with type 2 diabetes.
Meanwhile, the weight loss vaccine RES-010 is pioneering a new class of RNA medicines. This vaccine blocks an RNA molecule called miR-22, described as a "master controller" of many processes involved with obesity. RES-010 boosts the production and activity of mitochondria and helps convert white fat into brown fat.
An early study has started into the safety of the jab in people. Obese mice given RES-010 lost weight despite eating the same amount as mice not given the treatment. Researchers hope that the drug will lead to long-lasting weight loss through its effects on these functions.
Eli Lilly also published top line results from a study assessing the effectiveness of a new weight loss pill, orforglipron, among adults with type 2 diabetes. Over the course of a year, orforglipron lowered blood sugar by 2.2% compared with 1.4% with oral semaglutide at the highest doses. People taking the highest dose of orforglipron lost an average of 8.9kg during the course of the year, compared with 5.0 kg among those taking the highest dose of oral semaglutide.
As the research continues, both Tirzepatide and RES-010 show promising potential in the treatment and management of type 2 diabetes and obesity. However, it is essential to note that the manufacturer of RES-010 is yet to be identified in the available search results.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
